|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
63,980,000 |
Market
Cap: |
607.17(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.22 - $11.59 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 18.6 |
Insider 6 Months : 18.6 |
Insider 3/6 Months : 37.7 |
|
Guru Rank Number : 245 |
Guru Rank Value : 4.8 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,499,124 |
1,499,124 |
1,499,124 |
1,499,124 |
Total Buy Value |
$13,117,335 |
$13,117,335 |
$13,117,335 |
$13,117,335 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
Total People Sold |
1 |
2 |
2 |
4 |
Total Sell Transactions |
1 |
3 |
11 |
21 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Suliman Shehnaaz |
SVP, Corp Dev & Strategy |
|
2017-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Worboys Philip D |
SVP, Translational Science |
|
2017-05-20 |
4 |
D |
$36.83 |
$202,675 |
D/D |
(5,503) |
170,134 |
|
- |
|
Hegde Sharathchandra S |
SVP, Research |
|
2017-05-20 |
4 |
D |
$36.83 |
$190,669 |
D/D |
(5,177) |
165,313 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2017-05-20 |
4 |
D |
$36.83 |
$569,392 |
D/D |
(15,460) |
856,377 |
|
- |
|
Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
|
2017-05-20 |
4 |
D |
$36.83 |
$184,666 |
D/D |
(5,014) |
157,333 |
|
- |
|
Pasqualone Frank |
SVP, Chief Comm Ops Officer |
|
2017-05-20 |
4 |
D |
$36.83 |
$214,351 |
D/D |
(5,820) |
215,000 |
|
- |
|
Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
|
2017-05-20 |
4 |
D |
$36.83 |
$260,720 |
D/D |
(7,079) |
156,076 |
|
- |
|
Gala Renee D |
SVP, Chief Financial Officer |
|
2017-05-20 |
4 |
D |
$36.83 |
$248,713 |
D/D |
(6,753) |
221,299 |
|
- |
|
Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
|
2017-05-20 |
4 |
D |
$36.83 |
$260,204 |
D/D |
(7,065) |
156,406 |
|
- |
|
Young William D |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
35,124 |
|
- |
|
Oconnor Donal |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
15,000 |
|
- |
|
Whitesides George M |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
184,392 |
|
- |
|
Molineaux Susan |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
Ringrose Peter S |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
21,428 |
|
- |
|
Fore Henrietta |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
18,000 |
|
- |
|
Mitchell Dean J |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
18,000 |
|
- |
|
Malkiel Burton G |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
32,571 |
|
- |
|
Broshy Eran |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
18,000 |
|
- |
|
Gunderson Robert V Jr |
Director |
|
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
35,059 |
|
- |
|
Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
|
2017-03-07 |
4 |
S |
$30.80 |
$13,059 |
D/D |
(424) |
163,471 |
|
- |
|
Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
|
2017-03-06 |
4 |
S |
$31.52 |
$427,916 |
D/D |
(13,576) |
163,895 |
|
- |
|
Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
|
2017-03-03 |
4 |
S |
$31.86 |
$854,772 |
D/D |
(26,829) |
161,453 |
|
- |
|
Worboys Philip D |
SVP, Translational Science |
|
2017-02-20 |
4 |
D |
$33.78 |
$351,211 |
D/D |
(10,397) |
173,935 |
|
- |
|
Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
|
2017-02-20 |
4 |
D |
$33.78 |
$420,223 |
D/D |
(12,440) |
188,282 |
|
- |
|
Lee Junning |
Sr. VP, Technical Operations |
|
2017-02-20 |
4 |
D |
$33.78 |
$324,660 |
D/D |
(9,611) |
225,071 |
|
- |
|
530 Records found
|
|
Page 16 of 22 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|